Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF-based therapy for knee osteoarthritis
ACTRN12614001044617Phase 2Withdrawn
- Sponsor
- Dr David Mathers
- Start
- Jan 2015
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous adipose-derived stromal vascular fraction, platelet-rich plasma and hyaluronic acid in knee osteoarthritis (OA) (4 arms), sponsored by Dr David Mathers. Primary endpoint: Safety and tolerability. Planned start Jan 2015; status: withdrawn.
02
Drugs
autologous adipose-derived stromal vascular fractionplatelet-rich plasmahyaluronic acid
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12614001044617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001044617.